Search

Frauke Etal Bentzien

from Empire, MI
Age ~61
Get Report
Also known as:
Frances Bentzien, Frauke Bentzein, Frauke N
Related to:
Jonah Bentzien, 26
Connected to:
Wesley R Bentzig, 43Jennifer R Bentzley, 50Phillip A Bentzler, 64Elissa G Benudis, 63Silvia Benun, 61Julie A Benusa, 55Kelly A Benusa, 55Renee Benuska, 57George J Benvegno, 50Rosario W Benvengi, 40

Frauke Bentzien Phones & Addresses

  • Empire, MI
  • 10414 NW Brittney Ct, Portland, OR 97229
  • 2336 Cecilia Ave, San Francisco, CA 94116 (415) 664-0139
  • 10414 NW Brittney Ct, Portland, OR 97229 (415) 298-0930

Publications

Us Patents

Novel Antiangiogenic Peptide Agents And Their Therapeutic And Diagnostic Use

View page
US Patent:
20030186382, Oct 2, 2003
Filed:
Mar 27, 2001
Appl. No.:
09/819094
Inventors:
Richard Weiner - Muir Beach CA, US
Joseph Martial - Modave, BE
Ingrid Struman - Boncelles, BE
Robert Taylor - San Francisco CA, US
Frauke Bentzien - San Francisco CA, US
International Classification:
A61K038/27
C12P021/02
C07H021/04
C12N005/06
C07K014/61
US Classification:
435/069400, 435/325000, 435/320100, 530/399000, 514/012000, 536/023500
Abstract:
The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.

Novel Antiangiogenic Peptide Agents And Their Therapeutic And Diagnostic Use

View page
US Patent:
20040077054, Apr 22, 2004
Filed:
Nov 14, 2003
Appl. No.:
10/714067
Inventors:
Richard Weiner - Muir Beach CA, US
Joseph Martial - Esneux, BE
Ingrid Struman - Faimes, BE
Robert Taylor - San Francisco CA, US
Frauke Bentzien - San Francisco CA, US
Assignee:
The Regents of the University of California
International Classification:
C12P021/02
C12N005/06
C07H021/04
C07K014/61
US Classification:
435/069400, 435/320100, 435/325000, 530/397000, 536/023500
Abstract:
The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.

Novel Antiangiogenic Peptide Agents And Their Therapeutic And Diagnostic Use

View page
US Patent:
20080090750, Apr 17, 2008
Filed:
Oct 19, 2007
Appl. No.:
11/875308
Inventors:
Richard Weiner - Muir Beach CA, US
Joseph Martial - Modave, BE
Ingrid Struman - Boncelles, BE
Robert Taylor - San Francisco CA, US
Frauke Bentzien - San Francisco CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 38/00
A61P 43/00
C07K 16/00
US Classification:
514002000, 530300000
Abstract:
The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.

Novel Antiangiogenic Peptide Agents And Their Therapeutic And Diagnostic Use

View page
US Patent:
20080096795, Apr 24, 2008
Filed:
Oct 19, 2007
Appl. No.:
11/875323
Inventors:
Richard Weiner - Muir Beach CA, US
Joseph Martial - Modave, BE
Ingrid Struman - Boncelles, BE
Robert Taylor - San Francisco CA, US
Frauke Bentzien - San Francisco CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 38/00
A61P 43/00
C07K 16/00
US Classification:
514002000, 530300000
Abstract:
The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.

Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists And Antimicrotubule Agents

View page
US Patent:
20110301188, Dec 8, 2011
Filed:
Oct 16, 2009
Appl. No.:
13/124586
Inventors:
Geetha Shankar - Palo Alto CA, US
Frauke Bentzien - San Francisco CA, US
Peter Lamb - Oakland CA, US
David Matthews - San Francisco CA, US
Assignee:
EXELIXIS, INC. - South San Francisco CA
International Classification:
A61K 31/475
A61P 35/00
A61P 35/02
A61K 31/4192
US Classification:
514283, 514422
Abstract:
This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN, VINCASAR PFS, VCR), Vinblastin (VELBAN, VELSAR) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.
Control profile
Frauke Etal Bentzien from Empire, MI, age ~61 Get Report